Status:

TERMINATED

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Lead Sponsor:

Duke University

Collaborating Sponsors:

Janssen, LP

Conditions:

Schizophrenia

Eligibility:

All Genders

18-40 years

Phase:

PHASE4

Brief Summary

Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive fu...

Detailed Description

First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode pat...

Eligibility Criteria

Inclusion

  • male or female between 18-40 years of age
  • meet DSM-IV criteria for first-episode schizophreniform, schizophrenia or schizoaffective disorder

Exclusion

  • pregnant \& breast-feeding women
  • patients with known sensitivity to oral Risperdal

Key Trial Info

Start Date :

April 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00314613

Start Date

April 1 2006

Last Update

December 2 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

John Umstead Hospital

Butner, North Carolina, United States, 27509

2

Duke University Medical Center

Durham, North Carolina, United States, 27710